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Abstract Datafromseveralstudiesindicateanassociation
ofheadachewithanxietydisorders.Inthisstudy,weassessed
anddifferentiatedanxietydisordersin100headachepatients
by using the PSWQ (Penn State Worry Questionnaire)
screening tool for generalised anxiety disorder (GAD) and
the ACQ (Agoraphobic Cognitions Questionnaire) and BSQ
(Body Sensation Questionnaire) for panic disorder (PD).
Control groups were constructed: (1) on the basis of epide-
miologicalstudiesonPDandGADinthegeneralpopulation
and (2) by including neurological patients. 37.0% of head-
ache patients had a GAD. 27% of headache patients met the
scoreforPDintheBSQ,4.0%intheACQ.Signiﬁcantresults
were obtained in comparison to the general population
(p\0.001) and with regard to GAD in comparison with a
sample of neurological patients (p\0.005). The BSQ sig-
niﬁcantly correlated with the number of medication days
(p\0.005).The resultsconﬁrm the increased prevalenceof
GAD in headache patients. PD seems to increase the risk of
medication overuse.
Keywords Headache  Generalised anxiety disorder 
Panic disorder  Neurological patients  Drug use
Introduction
The increased comorbidity of mental disorders and head-
ache has been demonstrated by several epidemiological
studies [1, 2]. These studies often focus on the association
of depression and headaches. However, there are indica-
tions that the risk of suffering from an anxiety disorder
with coexisting headache is higher than the risk of suffer-
ing from a depression [3, 4].
Clinically, it is important to make a distinction between
the different anxiety syndromes. Migraine patients’ risk of
suffering from a panic disorder (PD) is up to ten times
higher than that of the general population [5]. Patients with
migraine and chronic headache have a four to ﬁvefold
increased risk of suffering from generalised anxiety dis-
order (GAD) [5, 6]. Some studies have also found that
headache patients suffer more frequently from GAD than
from PD [7]. Given the current state of research, the
ﬁndings are heterogeneous. In addition, only a few studies
speciﬁcally examine what speciﬁc type of anxiety disorder
headache that patients suffer from [8]. This is due to the
fact that screening for anxiety is more difﬁcult than
screening for depressive disorders because anxiety has
many manifestations and the physical symptoms of anxiety
are similar to symptoms of somatic diseases. A disorder-
speciﬁc diagnosis is useful because different anxiety dis-
orders have a different phenomenology and thus require
differential (pharmacological and psychotherapeutic)
treatment.
The possible presence of a co-morbid anxiety disorder is
important for various reasons. First, the prognosis is more
unfavourable when an anxiety disorder occurs simulta-
neously with headache [9]. Second, there are signiﬁcantly
higher costs for the health system if there is a co-morbid
anxiety disorder [10]. Third, quality of life is signiﬁcantly
more impaired when an anxiety disorder and headache are
co-morbid than when only one disease is present [11]. The
probability of a simple migraine developing into a trans-
formed migraine is increased if there is a co-morbid mental
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co-morbid mental disease more frequently than general
neurological patients [13, 14]. Little is known about the
speciﬁc anxiety disorders in headache patients.
This prospective study aims to investigate the preva-
lence of PD and GAD among a group of patients in a
tertiary headache clinic. The results are compared to the
prevalence of these anxiety disorders in the general popu-
lation and in outpatients not suffering from headache. We
further explore whether there is a relationship between
these anxiety disorders and the amount of pain medication
used by headache patients.
Methods
Study participants
We prospectively recruited patients presenting between
April 2009 and October 2009 at our outpatient tertiary
headache centre. A randomized age- and gender-matched
control group (n = 20) was drawn from the non-headache
outpatient clinic of our neurological department. The
exclusion criterion for both groups was the existence of a
depressive disorder (ICD-10: F32–F38 diagnoses), with the
additional exclusion criterion of any history of headache
and dementia for the control group. All patients gave their
informed consent prior to their inclusion in the study.
Characteristics of headache patients
The majority of the 100 headache patients included in the
study was female (37.2 ? 12.4 years). 8% of patients were
male (44.0 ? 15.9 years). 70% (n = 70) of patients suffered
from episodic migraine without aura (MoA), 10% (n = 10)
had episodic migraine with aura (MA), 3% (n = 3) had ten-
sion-type headache (TTH) and medication overuse headache
(MOH) was present in 17% (n = 17) of patients. 39.0%
(n = 39) of patients with migraine (MoA and MA) fulﬁlled
the criteria for chronic migraine according to the appendix
criteriaoftheInternationalHeadacheSociety(IHS)2006[15].
Characteristics of neurological patients
80.0% of the 20 patients in our control group were female
(41.6 ? 11.4 years), 20.0% were male (40.4 ? 13.0 years).
Table 1 shows the neurological diseases of the control group.
Material
The following standardized disorder-speciﬁc self-report
instruments were used:
(1) Screening for GAD—Penn State Worry Question-
naire (PSWQ) [16]
This questionnaire quantiﬁes pathological worry which,
according to DSM-IV, constitutes the cardinal feature of
GAD. It is a 16-item self-report measure of worry. The
items of the PSWQ are rated on a ﬁve-point Likert scale.
The cut-off value is a score of 49 in women and a score of
45 in men. Pathological worry is deﬁned as a one-dimen-
sional concept. The measure has been shown to have
excellent psychometric properties in clinical and non-
clinical samples; the internal consistency (Cronbach’s
alpha = 0.86–0.95) is good [17, 18].
(2) Screening for PD—Body Sensations Questionnaire/
Agoraphobic Cognitions Questionnaire [19]
The BSQ contains 17 items concerning the degree to
which patients fear somatic symptoms commonly associ-
ated with anxiety and panic attacks. The inventory assesses
the fear of certain body sensations. Items are rated on a
ﬁve-point Likert scale ranging from 1 = ‘‘not frightened or
worried by this sensation’’ to 5 = ‘‘extremely frightened
by this sensation’’.
The ACQ measures the frequency of fear-related cog-
nitions, the fear of negative social or health consequences
of fear. The ACQ contains 14 items (6 behavioural-social
and 8 physical items) rated on a ﬁve-point Likert format,
ranging from 1 = ‘‘the thought never occurs’’ to 5 = ‘‘the
thought always occurs when I am nervous’’.
Table 1 Diagnoses of the control group from the outpatient clinic at
the department of neurology
Diagnosis (ICD-10) n (%)
Myopathy G72.9 1 (5.0%)
Intracerebral haemorrhage in hemisphere, unspeciﬁed
I61.2
1 (5.0%)
Encephalitis, myelitis and encephalomyelitis, unspeciﬁed
G04.9
2 (10.0%)
Paraesthesia of skin R20.2 1 (5.0%)
Cerebral infarction due to unspeciﬁed occlusion or
stenosis of cerebral arteries I63.5
1 (5.0%)
Cervicobrachial syndrome M53.1 1 (5.0%)
Spinal stenosis M48.0 1 (5.0%)
Other and unspeciﬁed abnormalities of gait and mobility
R26.8
1 (5.0%)
Spastic diplegic cerebral palsy G80.1 2 (10.0%)
Vascular myelopathies G95.1 1 (5.0%)
Aneurysm of carotid artery I72.0 1 (5.0%)
Meningitis in bacterial diseases classiﬁed elsewhere G01 3 (15.0%)
Carpal tunnel syndrome G56.0 1 (5.0%)
Other speciﬁed endocrine disorders E34.8 1 (5.0%)
Hereditary ataxia, unspeciﬁed G11.9 1 (5.0%)
Neuroborreliosis G69.2 1 (5.0%)
ICD International Classiﬁcation of Diseases
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The cut-off is 2.3 for ACQ and 2.5 for BSQ. The internal
consistency (Cronbach’s alpha = 0.80–0.95) for the BSQ
is good; the internal consistency for the ACQ (Cronbach’s
alpha = 0.74–0.87) is satisfactory. The retest reliability is
between rtt = 0.63 and 0.8.
On the basis of current national epidemiological studies
on PD [20] and GAD [21], the expected prevalence of each
anxiety disorder was calculated for an age- and gender-
matched group of the general population. Both studies
presented their results in four age and gender groups. The
number n of headache patients was identiﬁed for each
class. Then the prevalence P of each anxiety disorder was
obtained for each sex and age group in the literature.
Finally, the expected number of patients with GAD and PD
was calculated for the general population by multiplying
n by P.
The estimation of dosages of acute medication of the
patients was done based on the detailed medical charts and
personal examinations and interviews.
This study was conducted in accordance with the ethical
principles of the Declaration of Helsinki.
Statistical analysis
Statistical analysis was performed using SPSS 17.0 for
Windows. Descriptive statistics consisted of frequency
counts and percentages or means and standard deviations.
Binary or ordinal factors were analysed with Chi-square for
comparisons between groups. To establish the relationship
between anxiety disorders and medication use behaviour,
the Spearman correlation coefﬁcient was calculated. Sig-
niﬁcance was set at p\0.05 in all cases.
Results
Anxiety disorders
37% (n = 37) of the headache patients (n = 100) also
suffered from GAD as measured by PSWQ, 27% of
headache patients had a BSQ score above C2.3 indicating a
PD concentrating on body-related sensations, while 4% had
a fear of fear-related cognitions, as measured by the ACQ
(see Fig. 1). A striking result of the screening is that the
combination of both anxiety disorders was found in 13% of
the headache population.
The group of headache patients (n = 100) differed sig-
niﬁcantly from the estimated general population (n = 100)
in regard to the manifestations of the anxiety disorders: this
means (v
2 = 26.22; df = 1; p = 0.000) for GAD and
(v
2 = 9.58; df = 1; p = 0.002) for PD (see Fig. 2).
The proportion of patients suffering from GAD was
signiﬁcantly higher among headache patients (n = 20) than
among neurological patients (n = 20) (v
2 = 5.23, df = 1,
p = 0.022). The screening of these two populations for PD
did not yield signiﬁcant results (v
2 = 1.56, df = 1,
p = 0.212) (see Fig. 3).
Headache patients took medication (triptan or analge-
sics) on 8.2 days per month on average. The correlation
between the BSQ score and the number of medication
days (r = 0.223, p = 0.028) was signiﬁcant. In contrast,
the correlation between the PSWQ (r = 0.90, p = 0.375)
and ACQ scores (r = 0.64, p = 0.530) (r = 0.64,
p = 0.530) and the number of medication days was not
signiﬁcant.
Fig. 1 Distribution of speciﬁc anxiety disorders in the population of
headache patients
Fig. 2 The prevalence of GAD and PD differs signiﬁcantly
(p\0.01) in patients with headache compared to the general
population
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Anxiety symptoms in headache patients
Despite the undisputed association between anxiety and
headaches, many studies focus on the co-morbidity of
depression and headache [22]. The lack of research on
headache and anxiety disorder and the risk factors of this
co-morbidity, such as chroniﬁcation, increased risk of
medication overuse, strongly reduced quality of life
when headache and anxiety disorders coexist, make a
differentiated investigation of anxiety disorders neces-
sary. In addition, different treatment approaches are
indicated, depending on what type of anxiety disorder is
present.
We found that headache patients are more likely to
suffer from GAD (37.0%) than from PD (27.0%). This
result is conﬁrmed by the HADAS study and a study by
Merikangas et al. [4, 23]. Corchs et al. [24] found that
44.6% of chronic migraine patients also suffered from a
GAD, corroborating the frequency of co-morbidity which
we found in our study. Other studies demonstrated that PD
is the most common anxiety disorder in headache patients
[25]. However, different theoretical approaches indicate
that GAD might be the more common anxiety disorder in
headache patients. Recent theoretical conceptualizations of
GAD suggest that ‘‘worry’’ (which constitutes the main
feature of GAD) may be used to dampen emotional and
somatic arousal [26, 27]. It is possible that headache
patients may use worry as a strategy to reduce the somatic
arousal that is associated with pain and as a result may
become prone to developing GAD [22].
Furthermore, pathological worry as a main feature of
GAD is similar to the cognitive style ‘‘catastrophizing’’.
The frequency of thought patterns with a tendency to
catastrophize (e.g. anticipation of pain, rumination in
response to the pain) has been shown for migraine patients
[28] and other chronic pain syndromes (e.g. low back pain,
rheumatoid arthritis) [29]. Catastrophizing is associated
with a decreased level of functioning, i.e. more pain, more
limitation by the pain and by pain behaviour and an
increased use of professional medical services. There are
other signiﬁcant factors associated with GAD, which
explain why GAD is the anxiety disorder which is most
commonly found in this study. These consist of the
knowledge that this anxiety disorder is relatively new, this
disease pattern is often not diagnosed correctly and GAD
patients typically consult primary care but rarely consult
professional psychiatric or psychotherapeutic services [18].
This might explain the frequent occurrence of GAD in a
somatic service centre such as the headache clinic.
In regard to PD, more patients scored higher on the
dimension of fear of body-related symptoms (27% higher
values in the BSQ) than on the dimension of fear-related
cognitions (4.0% reached cut-off in the ACQ). This ﬁnding
might indicate that particularly threatening assessment of
physical symptoms and the resulting fear of physical
symptoms in headache patients are more signiﬁcant than
the fear of the cognitive negative social or health conse-
quences of fear. The threat of physical sensations, which is
measured by the BSQ, is an aspect of anxiety sensitivity as,
for instance, measured on the anxiety sensitivity index
(ASI) that was originally conceived as an etiological factor
in PD [19]. Drahovzal et al. [30] demonstrated that high
ASI scores predict the occurrence of headache, pain
intensity and other physical symptoms associated with
headache. This result is remarkable as it was obtained in a
non-clinical sample, and yet anxiety sensitivity is a pre-
dictor of headache. What both anxiety disorders have in
common is the fact that they are not phobic anxiety
disorders.
Comparison of headache patients with the general
population with regard to anxiety symptoms
For headache patients, the probability of suffering from
GAD is about ﬁve times higher and the probability of
suffering from PD is about three times higher than for the
general population. This ﬁnding corresponds with the
results of other studies that also found an increased prev-
alence of anxiety disorders in headache patients [31, 32].
Senaratane et al. [33] found that two-third of anxiety dis-
order patients suffered from migraine, with twice as many
Fig. 3 The prevalence of GAD differs signiﬁcantly (p\0.05)
between headache patients and patients with non-headache neurolog-
ical diseases. The prevalence of PD does not differ signiﬁcantly
between the two groups
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order than vice versa.
Comparison of headache patients with neurological
patients with regard to anxiety symptoms
More than 50% of headache patients exhibit indications of
GAD in contrast to only one-ﬁfth of neurological patients.
The prevalence of PD did not differ signiﬁcantly between
the two groups, even if PD was found more frequently in the
subpopulation of headache patients than in the group of
general neurological patients. Other authors maintain the
importance of anxiety symptoms in neurological patients
[34, 35], but still there is not much data available [36].
Ekstrand et al. [13] found that 39% of neurological patients
displayed an underlying psychiatric disorder: depression
and somatoform disorder were the most prevalent disorders.
Those with a psychiatric disorder were less likely to have an
underlying neurological process as the cause of their
symptoms. The results of our study show that headache
patients in particular have an increased risk of having a
psychiatric disorder. There are indications that co-morbid
anxiety disorder in neurological patients is less adequately
diagnosed and treated than co-morbid depression [37].
Particularly, psychiatric disorders among neurological
patients increase the risk of a subsequent high number of
non-psychiatric hospital admissions. Somatoform disorders,
for example, have more than ﬁve times the risk for anxiety
and depression with almost four times the risk for high use
of hospital appointments [38]. Accordingly, the diagnosis
and the treatment of anxiety disorders is important in neu-
rological patients, and even more so in headache patients.
Anxiety and medication use
Higher scores in the BSQ correlate signiﬁcantly with the
amount of medication taken during acute pain, but there is
no correlation with the ACQ and the PSWQ. This might be
explained by the fact that threatening physical symptoms
are perceived as less threatening and an anxiety reduction
occurs when medication is taken early. PD patients typi-
cally carry fear-reducing items (e.g. sugar, medicines,
blood pressure monitor, and water), which can be seen on a
behavioural level as an avoidance strategy. Frequent
medication use also represents an avoidance strategy on a
behavioural level. For GAD, the avoidance strategy is
worry that takes place on a cognitive level.
Neurobiological connections between anxiety
and headache
Stress, strain and anxiety play an important role as trigger
factors of migraine or can contribute to the disorder
becoming chronic. One possible mechanism might be a
sympathetic activation [39] that is common in both GAD
and PD. It has been shown that high levels of fear and the
experience of stress increase the perception of pain [40]
and also that repeated experience of pain increases anxiety
[41]. The experience of anxiety and pain may thus be
considered as a reciprocal interaction. High scores on
anxiety questionnaires are able to predict the activation of
cortical areas responsible for pain perception [42]. From an
evolutionary perspective, fear and pain can be classiﬁed as
related qualities of experience which—as they serve as
warning and protection—fulﬁl a function that is essential
for survival. Knowing that cortical hyperexcitability plays
a pathogenic role in migraine [43], a connection to GAD
via noradrenergic dysfunctions is plausible. The locus
coeruleus-norepinephrine axis seems especially important
for the neurobiology of GAD [44]. The pharmacothera-
peutic inﬂuence of this axis in the context of migraine
prophylaxis with beta-blockers can reduce the frequency of
migraine attacks by decreasing neuronal excitability [45].
It can be expected that there are common physiological
processes. In the group of antidepressants, an action proﬁle
is documented for the serotonin–norepinephrine reuptake
inhibitor for migraine prophylaxis as well as for co-morbid
anxiety disorders [46]. On a genetic level, there is evidence
that migraine and anxiety are associated by way of the s
allele of the 5HTTLPR polymorphism of the serotonin
transporter gene [47]. The importance of the 5-HTTLPR
polymorphism is also demonstrated for PD [48].
Limitations
Due to the relatively low group size, this study can only
provide indications. The results should be conﬁrmed in
studies with larger samples. A further limitation is that the
headache and the control group are almost exclusively
composed of females. This applies particularly to the
comparison with the control group of neurological patients.
Another limitation is that the headache patients took trip-
tans and analgesics, whereas the neurological patients and
the subjects from the general population did not. The
diagnosis of other anxiety disorders, such as speciﬁc pho-
bia or social phobia, could also be important. In addition,
there may be a bias with regard to the degree of psycho-
pathology as the data were collected in specialised clinics.
Conclusion
Headache patients suffer from anxiety disorders more fre-
quently than the general population. GAD and the threat-
ening assessment of somatic symptoms in the context of
PD are of particular relevance. These symptoms may be
J Headache Pain (2011) 12:323–329 327
123directly related to an increased use of anti-pain medication.
Compared to neurological patients, headache patients are
more likely to suffer from a co-morbid anxiety disorder.
Psychiatric diagnostics with a focus on anxiety disorders
should therefore be established among neurological
patients. The aim should be to initiate an appropriate
therapy for anxiety disorders as soon as the disorder is
detected in order to minimise the risk of chroniﬁcation of
headache and to prevent increased use of health care
resources.
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